About This Webinar
Cultural competence and cultural humility are concepts that frame key components of an equitable health care system; one that is sensitive to patient diversity and embraces clinician patient communication that supports shared decision making. Health care professionals require both cultural competence and humility to interact effectively with their diverse patient communities. This webinar aims to share learning and provide actionable recommendations around practicing cultural competence and cultural humility in epilepsy care settings.

This webinar is hosted by the American Epilepsy Society in conjunction with Dartmouth Health and the Managing Epilepsy Well Network.

This webinar is supported by the Centers for Disease Control (CDC) and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,500,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

Presenters:
Elizabeth Felton, MD, PhD, FAES
Assistant Professor of Neurology and Biomedical Engineering
University of Wisconsin School of Medicine and Public Health

Moderator:
Elaine T. Kiriakopoulos, MD, MPH, MSc
Assistant Professor of Neurology
Geisel School of Medicine at Dartmouth College

Learning Objectives
At the end of this webinar, attendees should be able to:
1. Defining cultural competence and cultural humility
2. Describing why cultural competence and cultural humility are important in creating equitable and inclusive health care services and systems
3. Identifying, examining and challenging cultural assumptions, values and beliefs
4. Discussing methods to redress power imbalances in epilepsy care settings

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity’s content. Update for all courses this year.

Planning Committee and Faculty
Elaine T. Kiriakopoulos, MD, MPH, MSc
Assistant Professor of Neurology
Geisel School of Medicine at Dartmouth College

Elizabeth Felton, MD, PhD, FAES
Assistant Professor of Neurology and Biomedical Engineering
University of Wisconsin School of Medicine and Public Health

CME Reviewer
Elaine Sing-Wah Seto, MD, PhD

American Epilepsy Society Staff Planners
Alexis Griffith, MPH
Project Manager
American Epilepsy Society

Shawna Strickland, PhD, CAE, RRT, FAARC
Associate Executive Director, Programs
American Epilepsy Society

Cristina Graham
Director, Education and Professional Development
American Epilepsy Society

Melissa Ball, CAE, PMP
Manager, eLearning
American Epilepsy Society

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.